Saniona (SANION) Q3 2025 earnings summary

Executive summary

• Achieved significant progress in advancing CNS therapies, highlighted by major licensing deals and pipeline advancements.

• Secured USD 42.5 million upfront from Jazz Pharmaceuticals for SAN2355, with potential for up to USD 992.5 million in milestones and royalties.

• Selected SAN2668 as a first-in-class clinical candidate for severe pediatric epilepsy syndromes.

• Strong cash position enables acceleration of internal pipeline assets toward clinical milestones.

Financial highlights

• Q3 2025 revenue was SEK 410.7 million, up from SEK 7.2 million year-over-year, driven by licensing income.

• Operating profit for Q3 was SEK 359.9 million (previous year: loss of SEK 18.9 million).

• Net profit for Q3 reached SEK 329.6 million (previous year: loss of SEK 29.5 million).

• Cash and cash equivalents at period end were SEK 672.8 million, up from SEK 41.3 million.

• Basic EPS for Q3 was SEK 2.39, compared to a loss of SEK 0.26 per share last year.

Outlook and guidance

• Focus remains on advancing three internal first-in-class assets into clinical development.

• Anticipates near-term milestone payments of USD 17.5 million as partners initiate clinical studies.

• Expects to conduct IND/CTIS enabling toxicology studies for key programs in H1 2026.

• Partnership funding supports independent advancement of internal assets through Phase 2 proof-of-concept.